TOP TEN perturbations for 1553077_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553077_at
Selected probe(set): 1553077_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553077_at (1553077_at) across 6672 perturbations tested by GENEVESTIGATOR:

melanoma study 34 (metastatic) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-4.0739574
Number of Samples:40 / 2
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

split-thickness skin grafting study 1 / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-3.6848269
Number of Samples:6 / 8
Experimental split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-3.3613515
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

skin squamous cell carcinoma study 8 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):3.1542196
Number of Samples:11 / 14
Experimental skin squamous cell carcinoma study 8 (primary)
Primary tumor tissue from the skin of patients with primary squamous cell carcinoma (SCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

melanoma study 34 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-3.1477976
Number of Samples:40 / 4
Experimental melanoma study 34 (metastatic)
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain).
Control normal skin tissue
Normal skin tissue.

skin transplantation study 1 (7d) / split-thickness skin grafting study 1

Relative Expression (log2-ratio):3.0586166
Number of Samples:5 / 6
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.

melanoma study 34 (primary) / melanoma study 34 (in situ)

Relative Expression (log2-ratio):-2.840416
Number of Samples:14 / 2
Experimental melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).
Control melanoma study 34 (in situ)
Tumor tissue from the skin of patients with melanoma in situ.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):-2.7769394
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

Merkel cell carcinoma study 3 (metastatic) / normal skin tissue

Relative Expression (log2-ratio):-2.7593355
Number of Samples:11 / 64
Experimental Merkel cell carcinoma study 3 (metastatic)
Metastatic tumor tissue from different metastatic sites (skin, lymph node, parotid gland) of patients with Merkel cell carcinoma of the skin.
Control normal skin tissue
Normal skin samples from healthy donors.

psoriasis study 11 (lesional; brodalumab; 43d; 700mg) / psoriasis study 11 (lesional; placebo; 43d)

Relative Expression (log2-ratio):-2.7318916
Number of Samples:8 / 4
Experimental psoriasis study 11 (lesional; brodalumab; 43d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; placebo; 43d)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 43 (week 6) after treatment with placebo.